Topper Copies

Dr. Mehra is a senior drug developer at a leading pharmaceutical company in India, renowned for producing various medications, including lifesaving drugs critical for treating chronic and rare diseases. Since its inception, the company has emphasized the quality and affordability of its drugs. Recently, under revised government guidelines, pharmaceutical companies are required to market a finished product only after obtaining "satisfactory results" from tests on the ingredients. Additionally, they must retain a sufficient quantity of samples of both intermediate and final products to allow repeated testing or verification of a batch. Dr. Mehra's team is in the final stages of developing a new medication for a rare but life-threatening disease. This drug has shown promising results in clinical trials. However, there have been unresolved concerns about the long-term side effects of the drug, observed in a small percentage of trial subjects. Despite this, the company has not released any major drug in the past decade, leading to significant pressure from the board members to expedite the drug's release. (a) Identify the stakeholders in the above case study. (b) Discuss the ethical issues faced by Dr. Mehra. (c) Analyse the options available to Dr. Mehra in the above case. Which of these would you choose and why? (Answer in 250 words)

Zinnia Aurora, AIR 6, 2025

Medical ethics, first charted by Hippocrates, are founded on the cardinal principle of: 'First, do no harm'.

The pharmaceutical sector, in recent times, has been accused of selling 'toxic drugs of life' which has tarnished Indian exports' reputation worldwide, especially post Gambian deaths.

(a) Stakeholders

In addition, the entire rare diseases community and future drug discovery will be a stakeholder.

(b) Ethical issues involved 1. Drug resilience for customers and their health 2. Professional loyalty to company is in question 3. Breakdown of trust of Dr. Mehra in his company's seniors 4. Breach of trust towards customers on potential release 5. Future of self and employees owing to stagnation in releases by company 6. Stoppage of access of existent drugs of company if brand disreputed 7. Humane capitalism of ensuring right service delivery 8. Quality and profit vie on unbalanced pedestal

(c) Options available 1. Bend under pressure and release drug - +ve: promising drug for diseased; company loyalty intact; continuation of employee security - -ve: loss of common good; profit seeking 'nasty, brutish and greedy' man of Hobbes takes over; violation of legal structures 2. Refuse release and stop working on drug - +ve: ensures intellectual integrity; diseased's lives saved from complication; professionalism maintained - -ve: drug, if not released by Dr. Mehra, might be by someone else; ethics of company still questionable

According to me, Hippocratic oath applies to pharmaceuticals as well. Dr Mehra should:

| Action | Justification | |---|---| | Highlight cost and benefit to directors | See legal cost and reputational hazard for informed decision over greed | | Ensure other drugs are not flouting same rules | Clarity for company for corporate and medical ethics maintenance | | Look further into drug for addressing issues and ask directors for some time | Middle path with seeking long term efficient outcomes of foresight |

Thus, while a bird in hand is better than two in bush of Chanakya's, it is equally important to deliver 'Yogakshemam karmasu kaushalam' (efficiency via excellence).